On November 25, 2025 Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer, reported the completion of enrollment in its ongoing Phase 1b clinical trial of INTASYL siRNA PH-762. In connection with completing enrollment, Phio continues to treat additional patients in the fifth cohort at the highest dose concentration of PH-762. Pathology results for these patients are expected in Q1 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PH-762 is a potent silencer of the PD-1 gene implicated in various forms of skin cancer.

The Phase 1b clinical trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2 and 4 cutaneous squamous cell carcinoma (cSCC), Stage 4 melanoma, and Stage 4 Merkel cell carcinoma. Per the trial’s protocol, patients receive four injections of PH-762 at weekly intervals and pathologic response is assessed on day 36 after the initial injection of PH-762 (NCT# 06014086).

Thus far, a total of 18 patients with cutaneous carcinomas have completed treatment across five dose escalating cohorts in the Phase 1b trial. The cumulative pathologic response in 16 patients with cSCC include six with a complete response (100% clearance), two with a near complete response (> 90% clearance) and two with a partial response (> 50% clearance). A single patient with metastatic Merkel cell carcinoma had a partial response (> 50% clearance). Six patients with cSCC and one patient with metastatic melanoma had a pathologic non-response (< 50% clearance). No patients in the study have exhibited clinical progression of disease.

To date, there were no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects in the patients receiving intratumoral PH-762 in this trial. Moreover, PH-762 has been well tolerated in all enrolled patients in each escalating dose cohort.

"Completing enrollment in the Phase 1b trial for PH-762 marks a significant step forward in advancing a promising treatment option for skin cancer." said Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals. "We are deeply grateful to the patients, investigators, our partners, and our team for their help in successfully achieving this important milestone."

(Press release, Phio Pharmaceuticals, NOV 25, 2025, View Source [SID1234660943])

On November 25, 2025 Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, reported that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 in New York, New York. Company management will participate in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

(Press release, Fate Therapeutics, NOV 25, 2025, View Source [SID1234660942])

On November 25, 2025 AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, reported that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 37th Annual Healthcare Conference, New York, NY

Format – Fireside chat and 1×1 investor meetings
Date and Time – Tuesday, Dec. 2, 2025 at 1:30pm ET

Evercore 8th Annual Healthcare Conference, Coral Gables, FL

Format – Fireside chat and 1×1 investor meetings
Date and Time – Wednesday, Dec. 3, 2025 at 7:55am ET
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at View Source Replays of the webcasts will be available for at least 30 days following the events.

(Press release, AnaptysBio, NOV 25, 2025, View Source [SID1234660941])

On November 25, 2025 Zetagen Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company pioneering first-of-its-kind, intratumoral treatments for metastatic and primary breast cancer, reported the successful closure of its Series B1 financing round of $12,908,000. The round was 100% oversubscribed, reflecting strong investor confidence in the company’s proprietary Zeta Platform and its potential to transform breast cancer care.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds from this round will support the advancement of Zetagen’s lead candidate, ZetaMet (Zeta-BC-003) towards commercialization, accelerate clinical development of ZetaMast (Zeta-MBC-005), and complete preclinical studies & GMP manufacturing of ZetaPrime (Zeta-PBC-007).

"The strong demand in our Series B1 round highlights the promise of our Phase 2a clinical data for ZetaMet in treating metastatic breast cancer to bone," said Joe C. Loy, CEO of Zetagen Therapeutics. "At the core of these encouraging results is our discovery of a novel molecular pathway—triggered by our compounds activating a conserved nuclear receptor—which enables promising predictability in dosing and outcomes from bench to bedside."

Advancing the Zeta Platform
Zetagen’s Zeta Platform is the development of first-of-its-kind therapies for metastatic and primary breast cancer. Our novel approach via proprietary carriers with a singular injection, delivers tumoricidal compounds which minimize severe off-target side effects while increasing survival rates.

The platform includes:
ZetaMet (Zeta-BC-003): Targets metastatic breast cancer in bone, ceasing lytic activity, inhibiting pain, and regenerating new bone, all via a singular intratumoral injection, without systemic limitation, minimizing skeletal related events (fractures). We have completed a Phase 2a clinical trial at the University of British Columbia demonstrated Complete Response in treated lesions, full bone regeneration, and no skeletal-related events. Preliminary results to be presented at the upcoming SABCS conference.
ZetaMast (Zeta-MBC-005): is a novel hydrogel delivering two synergistic tumoricidal agents via a single intratumoral injection for breast cancer liver metastases (BCLM). Designed to localize treatment and reduce systemic toxicity, it has shown promising preclinical results—published in PLOS ONE and co-authored by Dr. Debu Tripathy—demonstrating reduced tumor burden, prevention of soft tissue metastases, and improved survival. A Phase 1b dose-escalation study is planned for 1H-2026.
ZetaPrime (Zeta-PBC-007): a neo-adjuvant treatment engineered for intratumoral administration following diagnosis. Utilizing proprietary hydrogel-like lipid carrier, formulation enables controlled release of 2 small molecules—one being novel molecular entity and or the ability to deliver a CDK4 or CDK4/6 protein inhibitor. Designed for solubility within adipose tissue, approach targets primary breast cancer, aiming to mitigate off-target effects, potentially reducing necessity for lumpectomies and mastectomies, decrease radiation exposure, and enhance patient survival. ZetaPrime’s single-dose in-vivo study showed improved survival and tumor suppression over Tamoxifen and Verzenio in a mouse mammary fat pad model; results will be presented at the upcoming SABCS conference.
Continued Momentum
The Series B1 funding follows a series of strategic milestones for Zetagen, including:

Expansion of the company’s global IP portfolio to 70+issued patents including Composition-of-Matter patents & claims on ZetaMet, ZetaMast, and ZetaPrime
Successful completion of the Phase 2a study of ZetaMet for metastatic breast cancer to bone
Accepted abstracts by SABCS on ZetaMet preliminary clinical results and ZetaPrime in-vivo results of head-to-head comparison towards Verzenio

(Press release, Zetagen Therapeutics, NOV 25, 2025, View Source [SID1234660940])

On November 25, 2025 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, reported that it will present at the Piper Sandler 37th Annual Healthcare Conference to take place on December 2-4, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 37th Annual Healthcare Conference

Date / Time: December 2, 2025, at 1:00 PM ET
Format: Fireside Chat
Location: New York, NY
Webcast Link: here

Webcasts from the conferences will also be available on UroGen’s Investor Relations website. A replay will be available on the site for approximately 90 days.

(Press release, UroGen Pharma, NOV 25, 2025, View Source [SID1234660939])